NABCO Resource Card on Breast Cancer Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

NEW YORK-The National Alliance of Breast Cancer Organizations (NABCO) has introduced the NABCO Resource Card, a quick reference guide to services and programs offered by the top breast cancer organizations in the United States.

NEW YORK—The National Alliance of Breast Cancer Organizations (NABCO) has introduced the NABCO Resource Card, a quick reference guide to services and programs offered by the top breast cancer organizations in the United States.

“Every day, we hear from women, ‘If I had only known about you,’” said Amy Langer, executive director of NABCO and a 12-year breast cancer survivor. “Even though there are many breast cancer resources available, too often women are not connecting with them. With support from Schering Corporation, we have created the NABCO Resource Card to offer a free directory to women and their families everywhere.”

One Million Cards

The card, sized to fit in a business envelope, concisely lists services in nine areas, including support groups, legal matters, clinical trials, volunteer groups, and information on breast cancer risks, diagnosis, and treatment. The toll-free telephone numbers of leading breast cancer organizations are provided.

One million of the cards will be distributed to more than 10,000 physicians’ offices and organizations cross the country. To receive a free NABCO Resource Card, call 1-800-610-5757.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content